Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cervavac (recombinant human papillomavirus recombinant quadrivalent vaccine, human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine) / Serum Institute of India
NCT06281119: Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years	Not yet recruiting	3	450	RoW	Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen	Serum Institute of India Pvt. Ltd., Bill and Melinda Gates Foundation	Human Papillomavirus Infection	12/25	05/26